Archived Content


2nd Annual  

Antibodies for Cancer Therapy April 30 - May 1

The field of antibodies directed against cancer is burgeoning and this is a huge growth area due to the success of drugs already on the market.  There still remain a number of challenges that include reducing immunogenicity, improving the targeting in solid tumors, and increasing the ability to kill cancer cells.  The pre-clinical and clinical results of recent new constructs will be shared, and the changes in regulation of antibodies will be reviewed.  The latest new approaches will be compared to more established techniques for filling the pipeline with future best-in-class drugs.

Meet the Scientific Advisory Board 

Soldano Ferrone, M.D., Ph.D., Professor, Department of Immunology, University of Pittsburgh Cancer - Biography 

Mitchell Ho, Ph.D., Head, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH - Biography 

Horacio G. Nastri, Ph.D., Director, Biotherapeutics Center for Therapeutic Innovation (CTI)-NY, Pfizer, Inc. 


Day 1 | Day 2 | Download Brochure 


4:00 - 6:00 pm Main Conference Registration




7:00 am Registration and Morning Coffee


8:30 Chairperson’s Opening Remarks

Mitchell Ho, Ph.D., National Cancer Institute, NIH

8:40 Monoclonal Antibodies: The Origins of Cancer Targeted Therapy

Ivor RoystonIvor Royston, M.D., Managing Partner, Forward Ventures (biography)

Monoclonal antibody-based therapeutics have a 30 year history and today are one of the major components of the oncologist’s armament in treating cancer and the forerunner of today’s targeted therapy of cancer. This talk will trace the evolution and ups and downs of these “magic bullets”.

9:10 Strategies and Challenges for the Next-Generation of Therapeutic Antibodies

Alain BeckAlain Beck, Ph.D., Associate Editor, mAbs; Head, Physico-Chemistry Department, Centre d’Immunologie Pierre Fabre (CIPF) (biography)

By analyzing the regulatory approvals of antibodies and related structures in the past 10 years, insights into the successful strategies can be gained. Many challenges will have to be faced in the next decade to bring more efficient and affordable antibody-based drugs to the clinic and will be discussed.

» 9:40 Featured Panel 

With Keynote Speakers: Future of Monoclonal Antibodies

Mitchell Ho, Ph.D., Head, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH

• Strategies to identify or select good targets: clinical relevance vs. biological effects (e.g., cell proliferation, apoptosis)
• Strategies to develop good antibodies: monoclonal, polyclonal, bispecific, alternative scaffolds
• Biosimilar antibodies and emerging markets (e.g., China, India)

10:10 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing



11:10 Discovery of Human Monoclonal Antibodies with Novel Functionality against Tumor Targets

Mitchell-HoMitchell Ho, Ph.D., Head, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH (biography)

My laboratory uses engineered antibody domains and in vitro tumor spheroid models to discover human antibodies that are (a) capable of neutralizing functionality of target by disturbing key signaling pathways, and (b) able to penetrate more effectively in solid tumors.


11:40 Co-Administration of Tight Junction Opener JO-1 Improves the Efficacy and Safety of Monoclonal Antibody Therapy of Cancer

Andre-LieberAndre Lieber, M.D., Ph.D., Professor, Department of Medicine, University of Washington (biography)

Epithelial cells maintain several intercellular junctions, a feature which is often conserved in epithelial cancers. These junctions inhibit the penetration of anti-cancer drugs into tumors. We generated a small recombinant protein, which triggers transient opening of intercellular junctions in epithelial tumors through binding to desmoglein 2, and enhances the anti-tumor effects of several therapeutic monoclonal antibodies, including trastuzumab and cetuximab.


Sponsored by
Vivalis small logo
12:10 pm Human Primary B Lymphocytes for the Rapid High Throughput Discovery of Native Therapeutic Monoclonal Antibodies

Majid Mehtali, Ph.D., Managing Director & CSO, VIVALIS

VIVA|SCREEN is a microarray-based single cell screening technology for the rapid isolation from human primary B lymphocytes of native biologically active mAbs. The microarray chips have been designed to contain from 62,500 to 234,000 wells with size and shape optimized for a single cell per well, enabling the rapid single cell analysis and retrieval, and antibody gene cloning. This technology was successfully applied for a series of targets, including for the discovery of antibodies produced by very rare B lymphocytes (<1/100,000,000 PBMCs).

12:40 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own



2:00 Chairperson’s Remarks

Horacio G. Nastri, Ph.D., Director, Biotherapeutics Center for Therapeutic Innovation, Pfizer, Inc.

2:05 DART Proteins for Cancer Therapy

Syd-JohnsonSyd Johnson, Ph.D., Vice President, Antibody Engineering, MacroGenics (biography)

MacroGenics Dual-Affinity Re-Targeting (DART®) proteins are among the most highly stable, potent, and easily manufactured biologics in this therapeutic class. The pre-clinical development of several DART proteins that recruit effector cells to solid and liquid tumor targets will be described.


2:35 Fcµ-Receptor Mediated Internalization of Antibody-Drug Conjugates: A Novel Approach to Selectively Target Cancer Cells

Berengere-VireBerengere Vire, Ph.D., Visiting Fellow, Hematology Branch, NHLBI, NIH (biography)

FcµR is consistently overexpressed at the cell surface of chronic lymphocytic leukemia (CLL) cells and rapidly internalizes upon IgM binding. We engineered an antibody-drug conjugate derived from the IgM-Fc portion as a novel agent for CLL immunotherapy.


3:05 Dual Targeting Multi-Functional DIG-Bodies Overcome Efficacy and Drug Resistant of Monospecific Antibody Therapeutics

Jin-San Yoo, Ph.D., CEO, PharmAbcine, Inc. (biography)

One of the leading pipeline from DIG-Bodies platform, DIG-KT neutralizing both VEGF-KDR and ANG-TIE2 pathways overcome Avastin resistant tumor. Overexpressing ANG2 in patients with Avastin longterm treatment is potential biomarker for Avastin resistant. In terms of efficacy, DIG-KT also performs superior to Tanibirumab, anti-KDR neutralizing fully human IgG in certain tumors.

3:35 An Efficient Route to Generate Bispecific Antibodies from Distinct Half-Antibodies

Christoph Spiess, Ph.D., Scientist, Antibody Engineering, Genentech (biography)

I will present on a technology to use the knobs-into-holes technology to generate bispecific antibodies with non-common light chains. The solution eliminates the need of linkers to prevent light chain mispairing. Each heavy chain is expressed with its corresponding light chain in separate Escherichia coli cultures. Individual half-antibodies are purified, combined and finally the bispecific antibody purified by conventional means.

4:05 Refreshment Break in the Exhibit Hall with Poster Viewing

4:45 Problem Solving Breakout Discussions

Concurrent problem solving breakout discussions, open to all attendees, speakers, sponsors, and exhibitors, provide a forum for discussing key issues and meeting potential collaborators. Plan to take part and explore these topics in-depth. Please pick a topic of your choice, find your table and join in.

Effective Penetration of Tumor Targets

Moderator:  Mitchell Ho, Ph.D., Head, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH

• Penetration of solid tumors and the blood-brain barrier: challenges and opportunities
• Role of cell junction proteins in tumor micronenvironment and identification of novel targets
• 3D tumor culture technologies and applications

Clinical Potential of Immunotherapy against Advanced Cancers

Moderator:  Richard A. Morgan, Ph.D., Staff Scientist, Surgery Branch, National Cancer Institute, NIH

• Immunotherapy categories
• Antibody-based therapy
• Cell-based therapy
• Vaccines/gene therapy
• What cancers to target
• Clinical trial design/end-points

Analyzing Trends for Success of mAbs

Moderator:  Alain Beck, Ph.D., Associate Editor, mAbs; Head, Physico-Chemistry Department, Centre d’Immunologie Pierre Fabre (CIPF)

• Target selection and validation
• Antibody structure optimization
• Alternative formats
• Synergestic mechanisms of action
• Biomarker identification and patient selection
• Biosimilar & Biobetter mAbs

Anticalins: Diagnostic and Therapeutic Applications

Moderator:  Laurent Audoly, Ph.D., CSO, Head, Research & Development, Pieris Ag

5:45-6:45 Welcome Reception in the Exhibit Hall with Poster Viewing
Emerald BioPoster Awards Sponsored by

Day 1 | Day 2 | Download Brochure